Cowen & Co. analyst Boris Peaker maintained a Buy rating on Endocyte (NASDAQ: ECYT) today. The company’s shares opened today at $18.89, close to its 52-week high of $20.85.
According to TipRanks.com, Peaker is a 5-star analyst with an average return of 13.3% and a 48.0% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals Inc, Stemline Therapeutics Inc, and Mersana Therapeutics Inc.
Currently, the analyst consensus on Endocyte is a Strong Buy with an average price target of $21.
See today’s analyst top recommended stocks >>
Based on Endocyte’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $11.56 million. In comparison, last year the company had a GAAP net loss of $11.74 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Endocyte, Inc. is a biopharmaceutical company, which engages in the development of targeted therapies for the treatment of cancer and inflammatory diseases. It uses a proprietary technology to create novel small molecule drug conjugates and companion imaging diagnostics for personalized targeted therapies.
